Haematologica
HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS
QUICK SEARCH:   [advanced]


     

Published online 27 May 2008
Haematologica, Vol 93, Issue 7, 1009-1016 doi:10.3324/haematol.12706
Copyright © 2008 by Ferrata Storti Foundation
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Bruchova et al. - Supplementary Appendix
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via ISI Web of Science (5)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bruchova, H.
Right arrow Articles by Prchal, J. T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bruchova, H.
Right arrow Articles by Prchal, J. T.
Related Collections
Right arrowRelated Article

Myeloproliferative Disorders

Aberrant expression of microRNA in polycythemia vera

Hana Bruchova1,2, Michaela Merkerova2, Josef T. Prchal1,3

1 School of Medicine, University of Utah, Salt Lake City, UT, USA
2 Institute of Hematology and Blood Transfusion, Prague
3 Department of Pathophysiology, 1st School of Medicine, Charles University, Prague, Czech Republic

Correspondence: Josef T. Prchal, University of Utah, School of Medicine, Hematology Division, SOM 5C210, 30 North 1900 East, Salt Lake City, Utah 84132, USA. E-mail:josef.prchal{at}hsc.utah.edu

Background: Polycythemia vera is a clonal hematopoietic stem cell disorder in which the JAK2 V617F mutation is observed in >95% of patients, but an as yet unidentified process appears to initiate the clonal expansion of hematopoiesis. Because microRNA regulate hematopoietic differentiation, we hypothesized that dysregulated expression of microRNA may contribute to the pathophysiology of polycythemia vera.

Design and Methods: We performed gene expression profiling in five patients with polycythemia vera and in five controls using CombiMatrix MicroRNA CustomArray. ANOVA identified deregulated microRNA in polycythemia vera, and their expression was studied in a larger set of samples by quantitative reverse transcriptase polymerase chain reaction. The expression of these microRNA was also analyzed in other myeloproliferative disorders.

Results: We observed down-regulation of let-7a and up-regulation of miR-182 in polycythemia vera granulocytes, up-regulation of miR-143, miR-145 and miR-223 in polycythemia vera mononuclear cells, up-regulation of miR-26b in polycythemia vera platelets, and down-regulation of miR-30b, miR-30c and miR-150 in polycythemia vera reticulocytes. JAK2 V617F frequency was positively correlated with miR-143 expression and inversely correlated with let-7a, miR-30c, miR-342 and miR-150. Transcript level of predicted target genes was determined, and overexpression of IRAK2 was detected in all granulocytes from patients with myeloproliferative disorders and in polycythemia vera reticulocytes. Abnormally high HMGA2 microRNA was found in myelofibrosis granulocytes.

Conclusions: Our study demonstrates that peripheral blood cells from patients with polycythemia vera have microRNA signatures distinct from those of controls. Our findings of aberrant microRNA expression underline the complexity of the molecular basis of polycythemia vera.

Key words: polycythemia vera, peripheral blood cells, microRNA expression, JAK2 V617F correlation.


Related Article

Molecular pathophysiology of Philadelphia-negative myeloproliferative disorders: beyond JAK2 and MPL mutations
Alessandro M. Vannucchi, Paola Guglielmelli
Haematologica 2008 93: 972-976. [Full Text] [PDF]





HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS
Copyright © 2008 by the Ferrata Storti Foundation.